cancer-congress-2019-scientifictracks

3 / 3

Note:
Cancer Congress 2019 Journal of Cancer Immunology &Therapy | Volume 2
Page 17
July 22-23, 2019 | Brussels, Belgium
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
CANCER SCIENCE AND THERAPY
2nd Global Congress on
THE TREATMENT OF PANCREATIC CANCERWITH NSC-631570 (UKRAIN)
Wassil Nowicky
Ukrainian Anti-Cancer Institute, Austria
Despite the fact that increasing amount of resources is put into the treatment of pancreatic cancer, one of
the most aggressive and lethal forms of cancerous diseases are the therapeutical outcome remains poor.
Chemotherapeutic agents such as Gemcitabine were found to have a positive influence on the quality of life
in pancreatic cancer patients; however, median survival times in patients treated with gemcitabine were only
marginally prolonged. Protocols using combinations of gemcitabine with 5-fluoruacil with or without folinic
acid or combinations of gemcitabine and cisplatinium have prolonged median survival, however these results
remain unsatisfactory. As such, finding a therapeutic agent that can further extend the median survival as well
as improve the quality of life of patients with pancreatic cancer remains a top priority. In recent years research
with the anti-cancer preparation NSC-631570 (Ukrain) has shown promising results in the treatment of unre-
sectable pancreatic cancer with actuarial survival rates of 86.7% after one year, 76.6% after two years, 46.7%
after three years and 23.3% after five years and a median survival time according to Kaplan-Meier regression
analysis of 33.8 months. These promising clinical results justified further research on the exact mechanism of
action as well as further possible beneficial effects of NSC-631570.
Wassil Nowicky, J Cancer Immunol Ther 2019, Volume 2
Wassil Nowicky is the Director of Nowicky Pharma and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). He finished
his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) in 1955 with graduation to“Diplomingeniueur”in
1960 which title was nostrificated in Austria in 1975. He became the very first scientist in the development of the anticancer protonic
therapy and is the Inventor of the preparation against cancer with a selective effect on basis of celandine alkaloids“NSC-631570”. He
used the factor that cancer cells are more negative charged than normal cells and invented the celandine alkaloid with a positive
charge thanks to which it accumulates in cancer cells very fast. He has been invited as an Honorable Speaker in many scientific
international congresses and conferences in USA, Australia, Japan, UAE and Europe. He has over 300 scientific articles dedicated to
cancer research. He is a Member of the New York Academy of Sciences, European Union for Applied Immunology and of the Amer-
ican Association for Scientific Progress, Honorary Doctor of the Janka Kupala State University in Grodno, Doctor “Honoris Causa” of
the Open International University on Complex Medicine in Colombo, Honorary Member of the Austrian Society of a name of Albert
Schweizer. He has received the award of merits from National Guild of Pharmacists of America, the Award of Austrian Society of
Sanitary, Hygiene and Public Health Services and others.
BIOGRAPHY